Dexamethasone/teclistamab/tocilizumab: Various toxicities and lack of efficacy.

A retrospective study was conducted on patients with relapsed/refractory multiple myeloma (R/R MM) who were treated with teclistamab. The study found that some patients developed cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and various infections such as Pseudomonas pneumonia, hospital-acquired pneumonia, and sepsis from a urinary source. In some cases, treatment with dexamethasone and tocilizumab for CRS did not show efficacy. Unfortunately, one patient died from a hospital-acquired infection. [Extracted from the article]